This is a lead compound identified as a first-in-class antibiotic from a de novo design campaign of over 750 new chemical entities. DNM0547 demonstrates high skin permeability, which provides high potential for topical treatment in Stage 1 and 2 Diabetic Foot Ulcers (DFUs). A mixture of DNM0547 and colistin is being studied for more advanced DFUs. DNM0547 has shown successful outcomes in several preclinical tests, including against many major multidrug-resistant bacteria. DNM0547 also finds potential use in the treatment of other conditions such as MRSA infections, cellulitis, drug resistant bacterial, ischemic limb and peripheral arterial infections.